本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Ultragenyx Pharmaceutical Inc

33.84
-2.3700-6.55%
盘后34.140.3000+0.89%19:36 EDT
成交量:99.32万
成交额:3,409.60万
市值:31.30亿
市盈率:-5.38
高:36.25
开:36.06
低:33.69
收:36.21
数据加载中...

公司资料

公司名字:
Ultragenyx Pharmaceutical Inc
交易所:
NASDAQ
成立时间:
2010
员工人数:
1294
公司地址:
60 Leveroni Court,Novato,California,United States
邮编:
94949
电话:
传真:
- -
简介:
Ultragenyx Pharmaceutical Inc.于2010年4月22日成立,是一家处于发展阶段的生物科技企业,公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化,该产品主要用于治疗罕见和极罕见的疾病,产品最初目标是用于治疗严重的,令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段,该疾病是一种渐进式的肌肉萎缩疾病。

董事

名称
职位
Daniel G. Welch
Chairman and Director
Emil D. Kakkis
Director,President and Chief Executive Officer
Clay B. Siegall
Director
Deborah Dunsire
Director
Lars G. Ekman
Director
Matthew K. Fust
Director
Michael Narachi
Director
William Aliski
Director

股东

名称
职位
Emil D. Kakkis
Director,President and Chief Executive Officer
Shalini Sharp
Chief Financial Officer and Executive Vice President
Camille L. Bedrosian
Chief Medical Officer and Executive Vice President
Dennis Huang
Chief Technical Operations Officer and Executive Vice President
Jayson Dallas
Chief Commercial Officer and Executive Vice President
John R. Pinion II
Chief Quality Officer and Executive Vice President of Translational Sciences
Karah Parschauer
General Counsel and Executive Vice President
Thomas Kassberg
Chief Business Officer and Executive Vice President